肿瘤标志物在肺癌联合诊断的临床应用探讨

梁卫平

[摘要] 目的 研究分析腫瘤标志物在肺癌联合诊断的临床应用探讨。方法 方便选取2016年10月—2017年10月该院收治的60例肺癌患者为研究对象，对照组患者为60名健康体检人员，分析肿瘤标志物与肺癌病例类型分布关系，详细记录患者相关临床指标。结果 实验组CEA水平为（56.78±6.54）μg/L，对照组CEA水平为（4.32±1.43）μg/L，差异有统计学意义（t=4.55，P<0.05）。实验组与对照组患者的CF211水平分别为（6.78±1.12）mg/L与（1.16±0.45）mg/L，差异有统计学意义（t=5.77，P<0.05）。实验组NSE水平为（33.12±4.32）μg/L，对照组NSE水平为（10.09±1.43）μg/L，差异有统计学意义（t=8.76，P<0.05）。腺癌CF211水平为（6.60±1.20）mg/L，CEA水平为（69.33±20.12）μg/L，与小细胞癌相比差异有统计学意义（t=6.89，P<0.05）。实验组CF211异常率为40.00%，CEA异常率为53.33%，NSE异常率为33.33%。结论 肿瘤标志物在肺癌联合诊断中具有重要临床价值，能够准确诊断肺癌，准确率较高，具有临床推广的意义。

[关键词] 肿瘤标志物；肺癌联合诊断；临床应用

[中图分类号] R734 [文献标识码] A [文章编号] 1674-0742（2018）04（c）-0045-03

Study on Clinical Application of Tumor Markers in the Lung Cancer Combined Diagnosis

LIANG Wei-ping

Department of Clinical Laboratory， Jining Tumor Hospital， Jining， Shandong Province， 272007 China

[Abstract] Objective To research and analyze the clinical application of tumor markers in the lung cancer combined diagnosis. Methods 60 cases of patients with lung cancer admitted and treated in our hospital from October 2016 to October 2017 were selected， and 60 cases of healthy physical examination people were selected as the control group， and the correlation between the tumor markers and lung cancer type was analyzed， and the related clinical indicators of patients were recorded in detail. Results The CEA level in the experimental group and in the control group was respectively（56.78±6.54）μg/L and（4.32±1.43）μg/L， and the difference was statistically significant（t=4.55， P<0.05）， and the CF211 level in the experimental group and in the control group was respectively （6.78±1.12）mg/L，（1.16±0.45）mg/L， and the difference was statistically significant （t=5.77， P<0.05） ， and the NSE level in the experimental group and in the control group was respectively （33.12±4.32）μg/L and （10.09±1.43）μg/L， and the difference was statistically significant（t=8.76， P<0.05）， and the adenocarcinoma CF211 level and CEA level were respectively （6.60±1.20）mg/L and （69.33±20.12）μg/L， and the differences were statistically significant compared with the small cell cancer（t=6.89， P<0.05） ， and the CF211 abnormal rate， CEA abnormal rate and NSE abnormal rate in the experimental group were respectively 40.00%， 53.33% and 33.33%. Conclusion The clinical value of tumor markers in the lung cancer combined diagnosis is important， which can accurately diagnose the lung cancer with higher accurate rate and clinical promotion value.

[Key words] Tumor marker； Lung cancer combined diagnosis； Clinical application

在临床治疗中，肺癌为一种常见疾病，初期临床症状并不明显，确诊后大部分处于晚期，治疗难度较高，威胁患者生命健康[1]。肺癌初期临床症状并不明显，易发生转移，发现时多处于晚期，初期患者机体肿瘤细胞合成分泌胚胎蛋白量异常，酶系统变异，相关研究表明，癌症早期诊断中应用肿瘤标志物灵敏性较高。为研究分析肿瘤标志物在肺癌联合诊断的临床应用，方便选取该院2016年10月—2017年10月收治的60例肺癌患者为研究对象，现报道如下。

1 资料与方法

1.1 一般资料

方便选取该院收治的60例肺癌患者为研究对象，对照组患者为60名健康体检人员，均充分知情同意。对照组中，年龄范围为44～67岁，平均年齡为（55.43±3.21）岁，女性患者为26例，男性患者为34例。实验组中，年龄范围为43～68岁，平均年龄为（55.20±3.12）岁，女性患者为25例，男性患者为35例，小细胞癌患者为7例，23例患者为腺癌，30例患者为鳞癌。两组患者一般资料差异无统计学意义（P>0.05），具有可比性。

1.2 方法

记录两组患者的可溶性细胞角蛋白19片断（CF211）、神经元烯醇化酶（NSE）及癌胚抗原（CEA）等临床指标，分析不同类型相关肿瘤标志物水平变化[2]。……